March 27, 2025 10:56 AM EDT

Equillium says graft-versus-host drug fails Phase 3, stock dives

Max Gelman

Senior Editor

A penny stock biotech reported that its acute graft-versus-host disease drug failed a late-stage trial, but it still plans to seek accelerated approval.

Equillium …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Equillium says graft-versus-host drug fails Phase 3, stock dives

Max Gelman

Senior Editor

Sign up to read this article for free.

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

Equi­l­li­um says graft-ver­sus-host drug fails Phase 3, stock dives

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

Equillium says graft-versus-host drug fails Phase 3, stock dives

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects